Cargando…

Topoisomerase 2 alpha as a predictor of response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer

Detalles Bibliográficos
Autores principales:	Shehata, M, Al-Attar, A, Reis-Filho, J, Ellis, I, Mukherjee, A, Chan, S
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875609/ http://dx.doi.org/10.1186/bcr2544

Ejemplares similares

Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer
por: Susini, Tommaso, et al.
Publicado: (2014)

Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer
por: Mukherjee, A, et al.
Publicado: (2010)

The prognostic and predictive power of redox protein expression for anthracycline-based chemotherapy response in locally advanced breast cancer
por: Woolston, Caroline M, et al.
Publicado: (2012)

Tumour necrosis factor-alpha levels as predictor factor on clinical response of anthracycline-based neoadjuvant chemotherapy in locally advance breast cancer patients: experimental research
por: Adrian, Kevin, et al.
Publicado: (2023)

CMR assessment of myocardial mechanics and tissue characterization in patients treated with Anthracycline chemotherapy for acute myeloid leukaemia
por: Miller, Christopher A, et al.
Publicado: (2012)

Evaluating the expression of heat shock protein 27 and topoisomerase II α in a retrospective cohort of patients diagnosed with locally advanced breast cancer and treated with neoadjuvant anthracycline-based chemotherapies
por: Zhuang, Yixuan, et al.
Publicado: (2023)

Early cardiac changes following anthracycline chemotherapy in breast cancer: a prospective multi-centre study using advanced cardiac imaging and biochemical markers
por: Grover, Suchi, et al.
Publicado: (2012)

Degree of diffuse fibrosis measured by MRI correlates with LV remodelling in childhood cancer survivors after anthracycline chemotherapy
por: Tham, Edythe B, et al.
Publicado: (2011)

Cardiovascular magnetic resonance imaging in early anthracycline cardiotoxicity
por: Smith, Gillian, et al.
Publicado: (2009)

Clinical predictors of physiological deterioration
por: Shehata, M, et al.
Publicado: (2010)

Does imaging correctly influence the surgical management in the setting of neoadjuvant chemotherapy?
por: Fatayer, H, et al.
Publicado: (2012)

Cardiac magnetic resonance characteristics of acute anthracycline-induced cardiotoxicity
por: Toro-Salazar, Olga H, et al.
Publicado: (2016)

Prognostic value of XIAP and survivin expression in locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy
por: Pluta, Piotr, et al.
Publicado: (2019)

Advances in anthracycline chemotherapy : epirubicin /
Publicado: (1984)

Delineation of anthracyclines and herceptin induced cardiotoxicity using contrast enhanced CMR
por: Hamirani, Yasmin S, et al.
Publicado: (2014)

Thioredoxin and related redox systems as targets in breast cancer
por: Woolston, CM, et al.
Publicado: (2010)

Correlation of post-neoadjuvant chemotherapy response on MRI with final histology in breast cancer patients
por: Mahatma, Anjum, et al.
Publicado: (2015)

Imaging the breast following neoadjuvant chemotherapy: does improvement of imaging findings in the axilla predict pathological response in the breast?
por: Williams, A, et al.
Publicado: (2012)

Topoisomerase II isoforms are required for HIV-1 reverse transcription
por: Sunnam, Lokeswara Balakrishna, et al.
Publicado: (2012)

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005)

Identification of proteins and signalling pathways involved in neoadjuvant chemotherapy responsiveness of breast tumours using proteomics
por: Greenwood, CR, et al.
Publicado: (2010)

PB.32. Type of breast surgery in patients undergoing neoadjuvant chemotherapy: role of DCE-MRI
por: Halim, M, et al.
Publicado: (2014)

Clinical and Pathological Response to Neoadjuvant Anthracycline Based Chemotherapy in women with breast cancer
por: Olfa, Gharbi, et al.
Publicado: (2010)

Increase in lesion enhancement on gadoxetic acid enhanced MRI is associated with complete response to neoadjuvant chemotherapy in colorectal liver metastases
por: Islam, S, et al.
Publicado: (2015)

Comparing extended and standard lymphadenectomy surgeries for bladder cancer (complications, final outcomes and effects of neoadjuvant chemotherapy)
por: Thiara, GS, et al.
Publicado: (2015)

Analysis of naphthoquinone derivatives as topoisomerase I inhibitors using fragment based QSAR
por: Virupaksha, Bastikar, et al.
Publicado: (2013)

Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives
por: Marinello, Jessica, et al.
Publicado: (2018)

MCPH1, a potential predictor for response to cancer chemotherapy
por: Bell, SM, et al.
Publicado: (2008)

Use of ultrasound elasticity imaging to monitor the response of a primary breast cancer to neoadjuvant chemotherapy in one patient in a pilot study
por: English, RE, et al.
Publicado: (2011)

Predictors of serious local complications in patients with severe acute pancreatitis
por: Hagiwara, A, et al.
Publicado: (2006)

Topoisomerase II expression as a determinant of chromosomal radiosensitivity and possible susceptibility in breast cancer
por: Bryant, PE, et al.
Publicado: (2008)

Chromosome 17 Centromere Duplication and Responsiveness to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer()()
por: Tibau, Ariadna, et al.
Publicado: (2014)

A MicroRNA Expression Signature In Taxane-anthracycline-based Neoadjuvant Chemotherapy Response
por: Zheng, Yi, et al.
Publicado: (2015)

CNA Landscape of HER2-Negative Breast Cancer in Anthracycline-Based Neoadjuvant Chemotherapy Regimens
por: Ibragimova, M. K., et al.
Publicado: (2023)

Use of MRI to predict response following neoadjuvant chemotherapy for breast cancer: how accurately can it guide surgical choice?
por: Tan, Sue, et al.
Publicado: (2015)

PB.40. What happens to the ductal carcinoma in situ in HER2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab?
por: Millican-Slater, R, et al.
Publicado: (2014)

Left ventricular mass by cardiac magnetic resonance imaging and adverse cardiovascular outcomes in patients treated with anthracycline-based chemotherapy
por: Neilan, Tomas G, et al.
Publicado: (2012)

Characterisation of the long-term effects of anthracycline-associated myocardial toxicity using cardiac MRI; a pilot study
por: Hughes, Marina L, et al.
Publicado: (2009)

Anthracycline Chemotherapy and Cardiotoxicity
por: McGowan, John V, et al.
Publicado: (2017)

Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy
por: Shehata, M, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_b233ofjtvsgqu149nqb4si94ql